862 related articles for article (PubMed ID: 22711702)
1. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
2. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
4. RANKL, denosumab, and giant cell tumor of bone.
Thomas DM
Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
[TBL] [Abstract][Full Text] [Related]
5. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.
Chawla S; Henshaw R; Seeger L; Choy E; Blay JY; Ferrari S; Kroep J; Grimer R; Reichardt P; Rutkowski P; Schuetze S; Skubitz K; Staddon A; Thomas D; Qian Y; Jacobs I
Lancet Oncol; 2013 Aug; 14(9):901-8. PubMed ID: 23867211
[TBL] [Abstract][Full Text] [Related]
7. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
[TBL] [Abstract][Full Text] [Related]
8. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
Federman N; Brien EW; Narasimhan V; Dry SM; Sodhi M; Chawla SP
Paediatr Drugs; 2014 Feb; 16(1):21-8. PubMed ID: 24114694
[TBL] [Abstract][Full Text] [Related]
9. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
10. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
12. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
[TBL] [Abstract][Full Text] [Related]
15. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.
Martin-Broto J; Cleeland CS; Glare PA; Engellau J; Skubitz KM; Blum RH; Ganjoo KN; Staddon A; Dominkus M; Feng A; Qian Y; Braun A; Jacobs I; Chung K; Atchison C
Acta Oncol; 2014 Sep; 53(9):1173-9. PubMed ID: 24834795
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
Lau CP; Huang L; Wong KC; Kumta SM
Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
[TBL] [Abstract][Full Text] [Related]
17. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
Ud Din N; Umer M; Park YK
Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
[No Abstract] [Full Text] [Related]
18. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
19. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
20. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
Sørensen AL; Hansen RL; Jørgensen PH
Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
